N	MRRB NOTIFICATION FOR	RM (GRAFT KIDNEY E	BIOPSY)
	oxes \blacksquare are provided, check (\checkmark) one or more boxes.	•	Office use:
*A. Centre Name:	nateures compaisory neta.		Centre:
*B. Date of Notificati	on (dd/mm/yyyy)		
*C. Type of Biopsy:	Graft kidney biopsy		
D.i) GFR: <u>(Au</u>	<u>to)</u>	D.ii) CKD Grade: (Auto)	
SECTION 1 : P	PATIENT PARTICULARS		
*1. Patient Name: Hj	/Hjh/Dato'/Dr		2. RN:
*3. Identification M	yKad / MyKid:	- Old IC:	
Number :	ther document No:	Specify type (eg.passport,	
*4. Date of Birth (dd/m	m/yy):	armed force ID): *5. Gender: Male	Female
*6. Ethnic	Malay	Chinese	(indian
Group:	Other M'sian, specify :	Foreigner, specify:	<u> </u>
SECTION 2 : C	CLINICAL DATA AT PRESENTA	ATION TO NEPHROLOGI	ST
1. Date: (dd/mm/yy) (If exact date not known, pls estimate date)	a. Date of ESKD:	b.Date of Transplant:	
2. Indications for biop	osy: (Tick where applicable)		
a. *Urine abnormalities	b. * Graft functio	on c. Ot	ther
Yes No	Stable	eterioration of graft function	Inconclusive previous biopsy Inadequate response to treatment
Hematuria and		deterioration of graft function	Evaluate response to treatment
Isolated prote	inuria Delayed	graft function immediate	Protocol biopsy Surveillance
Nephrotic ran	ge proteinuria	spiant	Others, specify:
Gross hematu	IIIA		
3. Primary Disease of	Biopsy proven glomerulonephritis, spec	·	Unknown
ESKD	Likely Glomerulonephritis, not biopsy prDrugs / toxic	roven Hypertension Hereditary nephritis, specify	
	nephropathy Diabetes Mellitus		··· Others, specify
4. Prior to Biopsy:		Not taken c. Dialysis required :	
		Not taken C. Dialysis required :	○ Yes○ No
	b. Height (cm):	Not taken	
5. Medication at Biops	sy i. Immunosuppresive Drugs		
	a. Corticosteroids	d. mTOR inhibitors	
	◯ Yes ◯ No	Yes No	
	b. Calcineurin inhibitors Yes No	© Everolimus © Sirolimus	
	Cyclosporin Tacrolimus		
	c. Anti-metabolites O Yes No		
	The state of the s		
		ophenolic sodium	
	ii. Induction therapy (if biopsy is done wi		
	IV methylprednisolone Basiliximab	Others, specify:	
	Thymoglobulin		
	Rituximab		

SECTION 3 : LAB DATA

1.	Haematology:		<u>Unit</u>			Valu	<u>e</u>					
	a. Hb		g/dL				Not availa	ble				
	b. TWC		10 ⁹ /L				Not availa	able				
	c. Platelet		10 ⁹ /L				Not availa	able				
2. *	Urine:											
	a. Urine RBC: b. Urine Protein:		No No	Urine dipsti	scopy		50 cells/ul) 3+) >50 cells/u			
b. Urine Protein: Yes No Not availa				ļ	+	2+ (3+					
c. 24 hrs Urine Protein,									Not a	Not available		
(g/day) d. Urine PCI/PCR				mg/mg					■ Not a	Not available		
	e. Urine ACR			mg/mg mg/g mg/mmol g/mmol mg/mmol					■ Not a	available		
3.	Biochemistry:									<u>Date</u>		
[a. Albumin	Au		g/L /L		© g/	'dL	■ Not	available			
	b. Creatinine (If on dialysis give pre dialysis result) *	Au		umol/L		(m	g/dL	Not	available			
	c. CMV PCR	Level:			IU/ml		detectable	Not o	lone			
		Level:			IU/mI		detectable	Not o				
		Level:			IU/mI		detectable	Not d				
ľ	a. 2	Level:			IU/mI		detectable	○ Not c				
		Level:			IU/ml		idetectable _	Not o				
		Levei:			IU/ml	Un	idetectable	Not o	ione			
	e. Others f. eGFR											
		Autoc	alc									
9	g. CKD Grade	Autoc	alc									

SECTION 4: HPE DATA *1a. Date Biopsy 1b. Is this the first allograft No ■ Biopsy Count: (dd/mm/yy): biopsy? Yes 2a. Biopsy specimen sent to: Name of Histopathology Lab: 2b. Biopsy read by: **Histopathologist Name:** 2c. HPE Report Number: 3. Biopsy Report(Hispathology a) Total Number of glomeruli reported: [If report shown 'no glom' please enter as '0'] Examination, HPE) b) Immunofluorescence/ IgA IgM C3 Immunohistochemistry C1q Kappa ■ PLA2R C4d Lambda Negative No → No glomeruli Not done Not sent Remark: c) Additional staining Congo red Others, specify d) Electronmicroscopy Yes No 4. HPE Diagnosis (specify): 5.HPE Diagnosis: ii) Diagnosis classification e. Other non-rejection changes ■ 1. Acute Tubular necrosis ■2. Interstitial fibrosis and tubular atrophy a. Normal biopsy 3. Infective: Report not conclusive **b.** Antibody mediated changes BK Polyoma Virus nephropathy No / not enough Acute ABMR glomeruli CMV nephritis Chronic Active ABMR Chronic ABMR Concomitant BKV CMV nephritis Others, specify : Bacterial pyelonephritis Suspicious (borderline) for acute T cell-**4.** Infiltrative: mediated rejection PTLD Others: d. T cell-mediated rejection ■ 5. CNI toxicity: 1. Acute TCMR Acute Type IA Type III Chronic Type IB **6.** Glomerulonephritis: Type IIA a. Type Type IIB Recurrent disease 2. Chronic active TCMR De Novo GN Grade IA Uncertain Grade IB b. Specify Histological Type: Grade II Minimal Change FSGS IgA nephropathy Membranous nephropathy Crescentic GN Post infectious GN Others, specify: **7.** Diabetic nephropathy 8. Interstitial nephritis Acute Chronic **9.** Advanced glomerulosclerosis 10. Infarcted Kidney **11.** Others, specify:

SECTION 4 : HPE DATA (continued)

6. Banff lesion score:	Not Available										
Total:	Banff lesion score	Abbr		0		1	2	3			
	6a. Interstitial inflammation	i	0	<10%		10-25%	② 26-50%	○ >50			
	6b.Tubulitis	t		None		1-4/tubular cross section or 10 tubular epithelial cells	○ 5-10	>10 or foci of tubular basement membrane destruction with i≥2 and t2 elsewhere			
	6c.Intimal arteritis	V		None		<25% luminal area lost	© ≥25% luminal area	Transmural and/or fibrinoid change and medial smooth muscle necrosis			
	6d.Glomerulitis	g	0	None		<25%	© 25-75%	○ >75%			
	6e.Peritubular capillaritis	ptc	0	<3 leukocytes /PTC		≥1 leukocyte in ≥ 10% of PTCs with max. of 3- 4/PTC	≥1 leukocyte in ≥ 10% of PTCs with max. of 5- 10/PTC	≥1 leukocyte in ≥ 10% of PTCs with max. of >10/PTC			
	6f. C4d	C4d		None		<10%	10-50%	>50%			
	6g. Interstitial fibrosis	ci	0	≤5%	0	6-25%	26-50%	>50%			
	6h. Tubular atrophy	ct	0	None	:	≤25%	26-50%	○ >50%			
	6i. Vascular fibrous Intimal thickening	cv	0	None	() :	≤25%	② 26-50%	○ >50%			
	6j. GBM double contours	cg		None		1a: only by EM 1b: ≤25% by ∟M	26-50%	○ >50%			
	6k.Mesangial matrix expansion	mm		None	() :	≤25%	② 26-50%	○ >50%			
	^{6l.} Arteriolar hyalinosis	ah		None	_	Mild to moderate	Mild to severe in >1	Severe in many			
	6mHyaline arteriolar thickening	aah	0	None		1 without circumferential	≥1 without circumferential	o circumferential			
	⁶ⁿ ·Total inflammation	ti		<10%	1	10-25%	26-50%				
	60-Inflammation in the area of IFTA	i-IFTA		<10%		10-25%	② 26-50%				